+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pegfilgrastim Market - Global Forecast 2026-2032- Product Image
Pegfilgrastim Market - Global Forecast 2026-2032- Product Image
Sale

Pegfilgrastim Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6158848
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pegfilgrastim Market is projected to reach USD 2.91 Billion in 2026. It is expected to continue growing at a CAGR of 5.33%, reaching USD 3.99 Billion by 2032.

Pegfilgrastim: Executive Summary and Market Context

Pegfilgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) used to reduce the duration of chemotherapy-induced neutropenia and the incidence of febrile neutropenia in appropriate patients. Its clinical value is linked to less frequent administration than short-acting filgrastim, supporting treatment adherence and reducing injection burden. Use is generally guided by chemotherapy risk, patient characteristics, treatment intent, local guidelines, and reimbursement conditions.

Care Delivery Is Shifting Toward Proactive Neutropenia Prevention

The landscape is moving toward risk-based prevention, standardized supportive-care pathways, and greater attention to treatment continuity. Hospitals and oncology networks increasingly emphasize chemotherapy scheduling, dose intensity, adverse-event monitoring, and timely intervention. Biosimilar availability is also reshaping procurement and formulary decisions, while home administration and digital follow-up can improve convenience when clinically appropriate. These shifts place greater importance on interchangeability policies, cold-chain reliability, patient education, and coordination between oncology teams, pharmacies, and payers.

Artificial Intelligence Strengthens Risk Assessment and Operational Coordination

Artificial intelligence can support pegfilgrastim use by identifying patients at elevated risk of febrile neutropenia from structured clinical data, treatment regimens, laboratory results, comorbidities, and prior complications. Predictive tools may help prioritize monitoring, coordinate administration around chemotherapy cycles, and identify patients needing follow-up. However, clinical validation, transparent model performance, data quality, privacy safeguards, and clinician oversight remain essential. AI should complement-not replace-guideline-based assessment and individualized medical judgment.

Regional Differences Reflect Access, Infrastructure, and Care Pathways

North America is characterized by established oncology infrastructure, active payer and formulary management, and broad experience with long-acting G-CSF. Europe combines mature supportive-care practice with country-specific reimbursement, health-technology assessment, and biosimilar policies. Asia-Pacific includes advanced oncology systems alongside settings where affordability, diagnostic capacity, and cold-chain access remain uneven. Latin America is shaped by public-private delivery differences and access variability across countries. The Middle East shows concentrated specialist capacity in some markets, while referral patterns and procurement structures influence availability. Africa faces pronounced differences in oncology infrastructure, laboratory access, financing, and treatment continuity, making implementation and supply reliability central considerations.

Economic and Political Groupings Shape Procurement and Access

Within ASEAN, differences in regulatory maturity, reimbursement, and hospital capacity create varied adoption conditions. BRICS members reflect diverse public-health systems, domestic manufacturing capabilities, and procurement priorities. The European Union benefits from shared regulatory structures while retaining national differences in reimbursement and purchasing. G7 countries generally have mature oncology services, but payer controls and guideline interpretation still affect utilization. GCC countries often combine centralized procurement with rapidly developing specialist care. NATO members span multiple health-system models, so alliance membership does not imply uniform access, clinical practice, or reimbursement.

Country-Level Priorities Vary Across Established and Developing Systems

Australia and Canada emphasize evidence-based reimbursement, regional access, and coordinated oncology pathways. Brazil, Mexico, India, and Russia face important differences between metropolitan and peripheral care, with affordability and supply continuity influencing treatment access. China is expanding oncology capacity while balancing centralized policy, domestic production, and regional variation. Japan and South Korea have sophisticated cancer-care systems with strong attention to dosing, reimbursement, and clinical protocols. France, Germany, Italy, Spain, and the United Kingdom operate within mature European frameworks, but national procurement, health-technology assessment, and prescribing practices differ. In the United States, utilization is influenced by clinical guidelines, payer policies, site of care, and the growing role of biosimilar competition.

Prioritize Evidence-Based Access, Reliable Delivery, and Patient-Centered Support

Industry leaders should align pegfilgrastim positioning with guideline-defined patient risk and demonstrate outcomes that matter to clinicians, payers, and patients. Strengthening supply-chain resilience, temperature-control processes, and administration support can reduce avoidable interruptions. Organizations should prepare differentiated evidence for biosimilar use, substitution rules, and real-world adherence while maintaining pharmacovigilance. Partnerships with oncology providers can improve education on timing, adverse-event recognition, and appropriate follow-up. Digital tools and AI should be deployed selectively, with governance frameworks that address validation, bias, cybersecurity, and accountability.

Research Methodology for a Rigorous Pegfilgrastim Assessment

A robust assessment should combine peer-reviewed clinical evidence, regulatory and treatment guidelines, health-technology assessments, reimbursement policies, procurement information, pharmacovigilance data, and credible public-health statistics. Analysis should distinguish approved indications from off-label practice and separate clinical efficacy, safety, access, and operational considerations. Regional, group, and country comparisons should account for differences in oncology burden, healthcare financing, biosimilar regulation, chemotherapy practice, laboratory capacity, and data availability. Findings should be triangulated across sources, dated clearly, and tested for consistency before interpretation.

Conclusion: Durable Value Depends on Integrated Supportive Care

Pegfilgrastim remains an important supportive-care option where prevention of chemotherapy-induced neutropenia is clinically appropriate. Its role is being shaped by risk-based oncology practice, biosimilar competition, decentralized care, reimbursement scrutiny, and digital coordination. Sustainable adoption will depend less on product availability alone than on reliable supply, evidence-aligned prescribing, equitable access, patient education, and accountable use of data and AI. Leaders that integrate these elements can strengthen treatment continuity while supporting safer, more efficient cancer care.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pegfilgrastim Market, by Product Type
7.1. Introduction
7.2. Biologic Pegfilgrastim
7.3. Biosimilars
8. Pegfilgrastim Market, by Dosage Form
8.1. Introduction
8.2. Injectable Solutions
8.3. Lyophilized Powder
8.4. Pre-filled Syringes
9. Pegfilgrastim Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. Pegfilgrastim Market, by Patient Demographics
10.1. Introduction
10.2. Geriatric Patients
10.3. Pediatric Patients
11. Pegfilgrastim Market, by Application
11.1. Introduction
11.2. Chemotherapy-Induced Neutropenia
11.3. Hematologic Malignancies
11.4. Radiation Therapy-induced Neutropenia
11.5. Solid Tumors
11.6. Stem Cell Transplantation
12. Pegfilgrastim Market, by End-User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Homecare Settings
12.4. Hospitals & Clinics
13. Pegfilgrastim Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Pegfilgrastim Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Pegfilgrastim Market, by Country
15.1. Introduction
15.2. United States
15.3. Germany
15.4. China
15.5. United Kingdom
15.6. India
15.7. Japan
15.8. Russia
15.9. Brazil
15.10. Canada
15.11. Italy
15.12. Mexico
15.13. France
15.14. Spain
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc.
17.2. Apotex Inc.
17.3. Biocon Biologics Limited
17.4. CinnaGen Inc.
17.5. Coherus BioSciences, Inc.
17.6. CuraTeQ Biologics Pvt. Ltd. by Aurobindo Pharma Ltd.
17.7. Dr. Reddy’s Laboratories Ltd.
17.8. Fresenius Kabi USA, LLC
17.9. Gennova Biopharmaceuticals Limited.
17.10. Intas Pharmaceuticals Ltd.
17.11. Mundipharma International Limited
17.12. Mylan N.V. by Viatris Inc.
17.13. Pfizer Inc.
17.14. Qilu Pharmaceutical Co., Ltd.
17.15. Sandoz Inc. by Novartis AG
17.16. Stada Arzneimittel AG
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Pegfilgrastim Market, Years Considered for the Study
FIGURE 2. Global Pegfilgrastim Market, Research Design
FIGURE 3. Global Pegfilgrastim Market, Research Framework
FIGURE 4. Global Pegfilgrastim Market, Data Triangulation
FIGURE 5. Global Pegfilgrastim Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Pegfilgrastim Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Pegfilgrastim Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Pegfilgrastim Market Size, by Dosage Form, 2025 vs 2032 (%)
FIGURE 9. Global Pegfilgrastim Market Size, by Dosage Form, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Pegfilgrastim Market Size, by Route of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Pegfilgrastim Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Pegfilgrastim Market Size, by Patient Demographics, 2025 vs 2032 (%)
FIGURE 13. Global Pegfilgrastim Market Size, by Patient Demographics, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Pegfilgrastim Market Size, by Application, 2025 vs 2032 (%)
FIGURE 15. Global Pegfilgrastim Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Pegfilgrastim Market Size, by End-User, 2025 vs 2032 (%)
FIGURE 17. Global Pegfilgrastim Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Pegfilgrastim Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Pegfilgrastim Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Pegfilgrastim Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Pegfilgrastim Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Pegfilgrastim Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Pegfilgrastim Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Pegfilgrastim Market Segmentation & Coverage
TABLE 2. Global Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 3. Global Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Biologic Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Biologic Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Biologic Pegfilgrastim Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Biosimilars Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Biosimilars Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Biosimilars Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 11. Global Injectable Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 12. Global Injectable Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 13. Global Injectable Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 14. Global Lyophilized Powder Market Size, by Region, 2017-2032 (USD Million)
TABLE 15. Global Lyophilized Powder Market Size, by Group, 2017-2032 (USD Million)
TABLE 16. Global Lyophilized Powder Market Size, by Country, 2017-2032 (USD Million)
TABLE 17. Global Pre-filled Syringes Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Pre-filled Syringes Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Pre-filled Syringes Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 21. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 22. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 23. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 24. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 28. Global Geriatric Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Geriatric Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Geriatric Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Pediatric Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Pediatric Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Pediatric Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 35. Global Chemotherapy-Induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Chemotherapy-Induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Chemotherapy-Induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Hematologic Malignancies Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Hematologic Malignancies Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Hematologic Malignancies Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Radiation Therapy-induced Neutropenia Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Radiation Therapy-induced Neutropenia Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Radiation Therapy-induced Neutropenia Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Stem Cell Transplantation Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Stem Cell Transplantation Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Stem Cell Transplantation Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 51. Global Ambulatory Surgical Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Ambulatory Surgical Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Ambulatory Surgical Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Asia-Pacific Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Asia-Pacific Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 63. Asia-Pacific Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 64. Asia-Pacific Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 65. Asia-Pacific Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 68. North America Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. North America Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 70. North America Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 71. North America Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 72. North America Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 73. North America Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 74. North America Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 75. Latin America Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Latin America Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 77. Latin America Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 78. Latin America Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 79. Latin America Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 80. Latin America Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 81. Latin America Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 82. Europe Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Europe Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 84. Europe Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 85. Europe Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 86. Europe Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 87. Europe Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 88. Europe Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 89. Middle East Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Middle East Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 91. Middle East Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 92. Middle East Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 93. Middle East Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 94. Middle East Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 95. Middle East Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 96. Africa Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Africa Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 98. Africa Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 99. Africa Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 100. Africa Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 101. Africa Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 102. Africa Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 103. Global Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 104. ASEAN Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. ASEAN Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 106. ASEAN Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 107. ASEAN Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 108. ASEAN Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 109. ASEAN Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 110. ASEAN Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 111. GCC Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 112. GCC Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 113. GCC Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 114. GCC Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 115. GCC Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 116. GCC Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 117. GCC Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 118. European Union Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 119. European Union Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. European Union Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 121. European Union Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 122. European Union Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 123. European Union Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 124. European Union Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 125. BRICS Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 126. BRICS Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 127. BRICS Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 128. BRICS Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 129. BRICS Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 130. BRICS Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 131. BRICS Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 132. G7 Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 133. G7 Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 134. G7 Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 135. G7 Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 136. G7 Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 137. G7 Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 138. G7 Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 139. NATO Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
TABLE 140. NATO Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 141. NATO Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 142. NATO Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 143. NATO Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 144. NATO Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 145. NATO Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 146. Global Pegfilgrastim Market Size, by Country, 2017-2032 (USD Million)
TABLE 147. United States Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 148. United States Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 149. United States Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 150. United States Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 151. United States Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 152. United States Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 153. United States Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 154. Germany Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 155. Germany Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 156. Germany Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 157. Germany Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 158. Germany Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 159. Germany Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 160. Germany Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 161. China Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 162. China Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 163. China Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 164. China Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 165. China Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 166. China Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 167. China Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 168. United Kingdom Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 169. United Kingdom Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 170. United Kingdom Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 171. United Kingdom Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 172. United Kingdom Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 173. United Kingdom Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 174. United Kingdom Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 175. India Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 176. India Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 177. India Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 178. India Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 179. India Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 180. India Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 181. India Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 182. Japan Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 183. Japan Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 184. Japan Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 185. Japan Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 186. Japan Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 187. Japan Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 188. Japan Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 189. Russia Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 190. Russia Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 191. Russia Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 192. Russia Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 193. Russia Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 194. Russia Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 195. Russia Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 196. Brazil Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 197. Brazil Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 198. Brazil Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 199. Brazil Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 200. Brazil Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 201. Brazil Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 202. Brazil Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 203. Canada Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 204. Canada Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 205. Canada Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 206. Canada Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 207. Canada Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 208. Canada Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 209. Canada Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 210. Italy Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 211. Italy Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 212. Italy Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 213. Italy Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 214. Italy Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 215. Italy Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 216. Italy Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 217. Mexico Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 218. Mexico Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 219. Mexico Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 220. Mexico Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 221. Mexico Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 222. Mexico Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 223. Mexico Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 224. France Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 225. France Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 226. France Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 227. France Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 228. France Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 229. France Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 230. France Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 231. Spain Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 232. Spain Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 233. Spain Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 234. Spain Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 235. Spain Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 236. Spain Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 237. Spain Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 238. Australia Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 239. Australia Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 240. Australia Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 241. Australia Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 242. Australia Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 243. Australia Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 244. Australia Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 245. South Korea Pegfilgrastim Market Size, 2017-2032 (USD Million)
TABLE 246. South Korea Pegfilgrastim Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 247. South Korea Pegfilgrastim Market Size, by Dosage Form, 2017-2032 (USD Million)
TABLE 248. South Korea Pegfilgrastim Market Size, by Route of Administration, 2017-2032 (USD Million)
TABLE 249. South Korea Pegfilgrastim Market Size, by Patient Demographics, 2017-2032 (USD Million)
TABLE 250. South Korea Pegfilgrastim Market Size, by Application, 2017-2032 (USD Million)
TABLE 251. South Korea Pegfilgrastim Market Size, by End-User, 2017-2032 (USD Million)
TABLE 252. Global Pegfilgrastim Market Share, by Key Player, 2025
TABLE 253. Global Pegfilgrastim Market, Key Experts

Companies Mentioned

  • Amgen Inc.
  • Apotex Inc.
  • Biocon Biologics Limited
  • CinnaGen Inc.
  • Coherus BioSciences, Inc.
  • CuraTeQ Biologics Pvt. Ltd. by Aurobindo Pharma Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Fresenius Kabi USA, LLC
  • Gennova Biopharmaceuticals Limited.
  • Intas Pharmaceuticals Ltd.
  • Mundipharma International Limited
  • Mylan N.V. by Viatris Inc.
  • Pfizer Inc.
  • Qilu Pharmaceutical Co., Ltd.
  • Sandoz Inc. by Novartis AG
  • Stada Arzneimittel AG

Related Topics

Related Reports

Pegfilgrastim Biosimilars Market Report 2026 - Product Image

Pegfilgrastim Biosimilars Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Pegfilgrastim Biosimilars Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Pegfilgrastim Biosimilars Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Long-Acting PEG-rhG-CSF Market Outlook 2026-2034: Market Share and Growth Analysis by Product Type (Pegfilgrastim (originator), Pegfilgrastim Biosimilars, Lipegfilgrastim, Eflapegrastim), Delivery Format, Indication, Distribution Channel - Product Image

Long-Acting PEG-rhG-CSF Market Outlook 2026-2034: Market Share and Growth Analysis by Product Type (Pegfilgrastim (originator), Pegfilgrastim Biosimilars, Lipegfilgrastim, Eflapegrastim), Delivery Format, Indication, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Chemotherapy Induced Neutropenia Market - Global Forecast 2026-2032 - Product Image

Chemotherapy Induced Neutropenia Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Chemotherapy-Induced Neutropenia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Chemotherapy-Induced Neutropenia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 143 Pages
  • Global
From

About the Market

Pegfilgrastim is a type of oncology drug used to treat neutropenia, a condition in which the body does not produce enough white blood cells. It is a long-acting form of filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, a type of white blood cell. Pegfilgrastim is used to reduce the duration and severity of neutropenia and the associated risk of infection in patients receiving chemotherapy for certain types of cancer. It is also used to reduce the duration of neutropenia and the associated risk of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Pegfilgrastim is available in both brand-name and generic forms. It is marketed by several pharmaceutical companies, including Amgen, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.